Santarus announces commercial launch of UCERIS ER tablets Santarus announced the U.S. commercial launch of UCERIS extended release tablets for the induction of remission in patients with active, mild to moderate ulcerative colitis. UCERIS was approved by the U.S. Food and Drug Administration on January 14. UCERIS was developed in collaboration with Cosmo Technologies Limited, a subsidiary of Cosmo Pharmaceuticals S.p.A. Upon first commercial sale of UCERIS, $7M is payable to Cosmo in cash or Santarus common stock, at Cosmo’s option.
News For SNTS From The Last 14 Days
Check below for free stories on SNTS the last two weeks.
Subscribe for More Information